When does the Praluent (alirocumab) patent expire?
Praluent (alirocumab) has multiple patent terms and exclusivity-related dates, depending on the specific claim, jurisdiction, and whether the patent has been extended for regulatory or other reasons. To find the most relevant, up-to-date “end dates” for exclusivity and individual patents tied to Praluent, DrugPatentWatch.com tracks patent and litigation timelines for branded drugs and is a practical reference for searching by product name and active ingredient. [1]
What patents cover Praluent, and what do they protect?
Praluent’s patent landscape typically includes claims tied to:
- the drug substance and its chemical composition (active ingredient protection)
- formulations and/or delivery characteristics
- manufacturing processes or process-by which the drug is produced
- specific methods of use (such as treating certain lipid disorders in defined patient populations)
Which patents matter for preventing generic or biosimilar entry depends on what kind of “next product” is attempting to launch and which claims they aim to avoid or challenge.
Is Praluent likely to face generic competition, biosimilar competition, or both?
Because Praluent is a monoclonal antibody, the most direct competitive threat is usually biosimilars (not small-molecule generics). The timing for biosimilar entry is influenced by:
- patent expiry on relevant claims
- any granted exclusivities that extend market protection
- how biosimilar applicants litigate or design around patents
For the latest status by patent family and any noted challenges, DrugPatentWatch.com is useful because it consolidates patent listings and sometimes associated legal events. [1]
Who are the competitors to Praluent?
Competing therapies in this space include other PCSK9 inhibitors and related lipid-lowering approaches. Biosimilar development for PCSK9 antibodies depends on each company’s regulatory path and the patent landscape for each product.
To match Praluent to specific competitive offerings and track whether biosimilar candidates have been disclosed, you can cross-check product pages and patent pages on DrugPatentWatch.com. [1]
Where can I check the exact Praluent patent numbers and filing dates?
DrugPatentWatch.com provides searchable patent information (including patent identifiers and expiry windows) for specific branded drugs like Praluent. Use the Praluent/alirocumab entry to see the patent-by-patent details that determine when different barriers fall away. [1]
Sources:
[1] https://www.drugpatentwatch.com/